Thanks to all who attended the CU Anschutz Innovation Forum
CU Innovations, Startup Toolbox and Academia Industry Alliance (AIA) hosted a 3-day event on June 10-12th that highlighted the diversity of innovation at the University of Colorado Anschutz Medical Campus.
Engaging presentations and panel discussions demystified the innovation journey. Key sessions covered company formation, building inclusive teams and career opportunities. CU researchers, start-ups and industry partners participated and networked at this successful event!
Congratulations to the winners of the Venture Showcase: NowVitals, pitched by Robin Deterding, MD, and Vināśa Oncology, pitched by Sujatha Venkataraman, PhD!
(1/19)
(2/19)
(3/19)
(4/19)
(5/19)
(6/19)
(7/19)
(8/19)
(9/19)
(10/19)
(11/19)
(12/19)
(13/19)
(14/19)
(15/19)
(16/19)
(17/19)
(18/19)
(19/19)
Agenda
Building upon the success of last year's Stories of Women-Led Innovation Event, this forum continued highlighting the achievements and challenges faced by our women innovators and demystifying the innovation pathway through presentations and panel discussions. Sessions covered intellectual property protection, building inclusive teams and addressing bias in the context of academic innovation.
Attendees were excited to hear from our keynote speaker, Gitanjali Rao, aspiring scientist, inventor and author!
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
This event aimed to educate and inspire entrepreneurs at all stages. Featuring panels on company formation, funding biomedical discoveries and creating strategic alliances, each session included interactive elements and the chance to network with potential partners from the Anschutz campus and beyond.
Attendees got to know Jodie Morrison, CEO of Q32 Bio, and Kimberly Muller, Executive Director of CU Innovations, through their Fireside Chat Keynote.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Congratulations to the judge vote winner, NowVitals pitched by Robin Deterding, MD, and the audience vote winner, Vināśa Oncology pitched by Sujatha Venkataraman, PhD!
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
With sessions featuring scientific talks, career panels, and a 2-hour networking lunch, RMBTS offered a prime platform to highlight scientific advancements and career opportunities, and foster collaboration within Colorado's scientific community.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Aaron Krueger PhD
Senior Scientist, Drug Product Development, Umoja Biopharma
Aaron graduated with his PhD in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. He then completed a post-doctoral fellowship at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences with a focus on characterizing sub-visible particles in protein therapeutics. Aaron then worked as a scientist at KBI Biopharma, Inc. in the Particle Characterization Core focusing on forensic particle analysis, biophysical characterization, and stability of biotherapeutics. He recently began as a Senior Scientist at Umoja Biopharma in Drug Product Development where he focuses on drug product compatibility, stability, and process improvements for a novel lentiviral vector drug product.
Event Sponsors
Thank you to our sponsors for making this forum possible! We are greatly appreciative of your continued support.
PLATINUM SPONSORS:
SPONSORS:
